Price
Target price
?
?
-0.680%
-0.085
-0.680%
€27.97
08:03 / Frankfurt
WKN: A2AFXS / Symbol: CRVS / Name: Corvus / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Corvus
sharewise wants to provide you with the best news and tools for Corvus, so we directly link to the best financial data sources.
Financials
News
Corvus Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Corvus Pharmaceuticals, Inc.? Here are five stocks we like better.
- Corvus reported a wider Q2 loss as research and development spending rose to $16 million for
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Immuno-oncology specialist Corvus Pharmaceuticals (NASDAQ:CRVS) reported a recent insider buy amid a year of sharp share price gains.
On June 11, 2026, David Scott Moore, acquired the direct
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
On May 15, 2026, Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals (NASDAQ:CRVS), acquiring 1,100,000 shares in the first quarter for an estimated $17.55 million based on